You just read:

Audentes Therapeutics Announces MHRA Approval of Clinical Trial Authorisation Application for AT342 to Treat Crigler-Najjar Syndrome

News provided by

Audentes Therapeutics, Inc.

13 Nov, 2017, 07:00 GMT